Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tretinoin

FDA-approved product (solution, topical), marketed as Panretin, Absorica, Absorica Ld and 17 more.

Registered studies
21
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Tretinoin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Acute promyelocytic leukemia
  • Eczematoid dermatitis
  • Freckles
  • Hyperpigmentation of the skin
  • Kaposi's sarcoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Retinoids for topical use in acne; Retinoids for treatment of acne; Agents for dermatitis, excluding corticosteroids; Retinoids for cancer treatment
FDA pharmacologic class
Retinoid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Tretinoin, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

21registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tretinoin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tretinoin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

    NCT05259722 · start 2022-06-15

    Registered record
    Registry ID
    NCT05259722
    Conditions
    Chronic Hand Eczema
    Interventions
    Delgocitinib; Toctino
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-06-15
    Completion
    2023-12-05
    Enrolment
    513

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hand Eczema
    InterventionDelgocitinib; Toctino
    PhasePhase 3
    Registry statusCompleted

  • Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

    NCT05077813 · start 2021-12

    Registered record
    Registry ID
    NCT05077813
    Conditions
    Tuberculosis
    Interventions
    13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB); 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB); All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB); All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB); 13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB); The standard therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-12
    Completion
    2022-02
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Intervention13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB); 9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB); All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB); All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB) +2 more
    PhasePhase 2
    Registry statusUnknown

  • Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

    NCT05016349 · start 2021-08

    Registered record
    Registry ID
    NCT05016349
    Conditions
    Breast Cancer Female
    Interventions
    All trans-retinoic acid; 13-Cis Retinoic Acid plus Tocopherol; Mifepristone; Cannabidiol; 9 cis retinoic acid; Tamoxifen; Standard therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-08
    Completion
    2021-12
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female
    InterventionAll trans-retinoic acid; 13-Cis Retinoic Acid plus Tocopherol; Mifepristone; Cannabidiol +3 more
    PhasePhase 3
    Registry statusUnknown

  • Dupilumab in Severe Chronic Hand Eczema

    NCT04512339 · start 2020-08-01

    Registered record
    Registry ID
    NCT04512339
    Conditions
    Hand Eczema
    Interventions
    Dupilumab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-08-01
    Completion
    2022-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand Eczema
    InterventionDupilumab; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema

    NCT03026946 · start 2017-05-29

    Registered record
    Registry ID
    NCT03026946
    Conditions
    Hand Eczema
    Interventions
    Alitretinoin; cyclosporin A
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-05-29
    Completion
    2022-07
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand Eczema
    InterventionAlitretinoin; cyclosporin A
    PhasePhase 3
    Registry statusUnknown

  • Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema

    NCT03026907 · start 2016-05

    Registered record
    Registry ID
    NCT03026907
    Conditions
    Hand Eczema
    Interventions
    Alitretinoin; Azathioprine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-05
    Completion
    2019-12
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand Eczema
    InterventionAlitretinoin; Azathioprine
    PhasePhase 3
    Registry statusUnknown

  • Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin

    NCT01538732 · start 2012-03

    Registered record
    Registry ID
    NCT01538732
    Conditions
    Lichen Planus (LP)
    Interventions
    alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2012-03
    Completion
    2014-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLichen Planus (LP)
    Interventionalitretinoin
    PhasePhase 2
    Registry statusUnknown

  • Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus

    NCT01407679 · start 2011-08

    Registered record
    Registry ID
    NCT01407679
    Conditions
    Lupus Erythematosus, Cutaneous
    Interventions
    Alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-08
    Completion
    2014-04
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Erythematosus, Cutaneous
    InterventionAlitretinoin
    PhasePhase 2
    Registry statusTerminated

  • Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis

    NCT01245140 · start 2011-04-26

    Registered record
    Registry ID
    NCT01245140
    Conditions
    Psoriasis
    Interventions
    alitretinoin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-04-26
    Completion
    2014-04-16
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    Interventionalitretinoin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease

    NCT01261923 · start 2010-12

    Registered record
    Registry ID
    NCT01261923
    Conditions
    Hepatic Insufficiency
    Interventions
    Alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2010-12
    Completion
    2011-08
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Insufficiency
    InterventionAlitretinoin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Single Dose of 9-cis-retinoic Acid in Hepatic Patients

    NCT01891526 · start 2010-12

    Registered record
    Registry ID
    NCT01891526
    Conditions
    Hepatic Insufficiency
    Interventions
    9-cis-retinoic acid
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-12
    Completion
    2012-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Insufficiency
    Intervention9-cis-retinoic acid
    PhaseNot recorded
    Registry statusCompleted

  • Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.

    NCT01231854 · start 2010-11

    Registered record
    Registry ID
    NCT01231854
    Conditions
    Atopic Dermatitis
    Interventions
    Ciclosporin; Alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-11
    Completion
    2013-03
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionCiclosporin; Alitretinoin
    PhasePhase 4
    Registry statusTerminated

  • Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

    NCT00817063 · start 2009-01-08

    Registered record
    Registry ID
    NCT00817063
    Conditions
    Eczema
    Interventions
    alitretinoin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-01-08
    Completion
    2012-04-26
    Enrolment
    599

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEczema
    Interventionalitretinoin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Alitretinoin in the Treatment of Chronic Hand Eczema

    NCT00519675 · start 2007-05

    Registered record
    Registry ID
    NCT00519675
    Conditions
    Eczema
    Interventions
    alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-05
    Completion
    Not recorded
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEczema
    Interventionalitretinoin
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

    NCT00309621 · start 2006-04

    Registered record
    Registry ID
    NCT00309621
    Conditions
    Hand Dermatoses
    Interventions
    alitretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-05
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand Dermatoses
    Interventionalitretinoin
    PhasePhase 3
    Registry statusCompleted